A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling

Molecular Pharmacology

Volumn 69, Issue 4, 2006, Pages 1288-1295

  Ii, Masayuki ^a   Matsunaga, Naoko ^a   Hazeki, Kaoru ^b   Nakamura, Kazuyo ^a   Takashima, Katsunori ^a   Seya, Tsukasa ^c   Hazeki, Osamu ^b   Kitazaki, Tomoyuki ^a   Iizawa, Yuji ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXENE DERIVATIVE; ETHYL 6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL]CYCLOHEX 1 ENE 1 CARBOXYLIC ACID; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; TAK 242; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CYTOKINES; ENZYME ACTIVATION; MAP KINASE SIGNALING SYSTEM; MICE; NITRIC OXIDE; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SULFONAMIDES; TOLL-LIKE RECEPTOR 4;

EID: 33645097021     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.019695     Document Type: Article

References (40)

1. Alexopoulou L, Holt AC, Medzhitov R, and Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature (Lond) 413:732-738.
2. Byrd-Leifer CA, Block EF, Takeda K, Akira S, and Ding A (2001) The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31:2448-2457.
3. Christ WJ, Asano O, Robidoux AL, Perez M, Wang Y, Dubuc GR, Gavin WE, Hawkins LD, McGuinness PD, Mullarkey MA, et al. (1995) E5531, a pure endotoxin antagonist of high potency. Science (Wash DC) 268:80-83.
4. da Silva Correia J, Soldau K, Christen U, Tobias PS, and Ulevitch RJ (2001) Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J Biol Chem 276:21129-21135.
5. Dunne A and O'Neill LA (2005) Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett 579:3330-3335.
6. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, and Duff GW (1988) Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2:706-709.
7. Ellingsen E, Morath S, Flo T, Schromm A, Hartung T, Thiemermann C, Espevik T, Golenbock D, Foster D, Solberg R, et al. (2002) Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit 8:149-156.
8. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick GD, Bloedow DC, et al. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock but fails to alter host responses to sublethal endotoxemia. J Clin Investig 89:1551-1557.
9. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, and Golenbock DT (2003) LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the toll adapters TRAM and TRIF. J Exp Med 198:1043-1055.
10. Fort MM, Mozaffarian A, Stover AG, da Silva Correia J, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, et al. (2005) A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 174:6416-6423.
11. Guha M and Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85-94.
12. Guzik TJ, Korbut R, and Adamek-Guzik T (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54:469-487.
13. Hehlgans T and Pfeffer K (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115:1-20.
14. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature (Lond) 408:740-745.
15. Hopkins PA and Sriskandan S (2005) Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 140:395-407.
16. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, and Schwarz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185-192.
17. Linton MF and Fazio S (2003) Macrophages, inflammation and atherosclerosis. Int J Obes Relat Metab Disord 27:S35-S40.
18. Lorenz E, Mira JP, Frees KL, and Schwarz DA (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028-1032.
19. MacDermott RP (1996) Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 31:907-916.
20. Misko TP, Schilling RJ, Salvemini D, Moore WM, and Currie MG (1993) A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214:11-16.
21. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, et al. (2003) Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 304:1093-1102.
22. Muzio M and Mantovani A (2000) The Toll receptor family. Allergy 56:103-108.
23. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, and Miyake K (2002) Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3:667-672.
24. Norman JG, Sutton ET, Franz MS, and Baker CH (1995) Maintenance of dynamic microvascular function and structure in a rat model of endotoxic shock by blockade of the interleukin-1 receptor. Shock 3:369-375.
25. O'Neill LA (2003) Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3:396-403.
26. Oshiumi H, Matsumoto M, Funami K, Akazawa T, and Seya T (2003a) TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 4:161-167.
27. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, and Seya T (2003b) TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-β. J Biol Chem 278:49751-49762.
28. Parratt JR (1997) Nitric oxide. A key mediator in sepsis and endotoxaemia? J Physiol Pharmacol 48:493-506.
29. Raza A (2000) Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis and myelodysplastic syndromes. Microsc Res Tech 50:229-235.
30. Ricciardolo FL, Sterk PJ, Gaston B, and Folkerts G (2004) Nitric oxide in health and disease of the respiratory system. Physiol Rev 84:731-765.
31. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, and Marshak-Rothstein A (2005) Toll-like receptors, endogenous ligands and systemic autoimmune disease. Immunol Rev 204:27-42.
32. Rossignol DP and Lynn M (2002) Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 6:483-488.
33. Sausa AR, Lane SJ, Nakhosteen JA, Lee TH, and Poston RN (1996) Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 154:1061-1066.
34. Schwacha MG (2003) Macrophages and post-burn immune dysfunction. Burns 29:1-14.
35. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, and Kimoto M (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Tolllike receptor 4. J Exp Med 189:1777-1782.
36. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, and Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of Gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451.
37. Triantafilou M, Triantafilou K, and Fernandez N (2000) Rough and smooth forms of fluorescein-labelled bacterial endotoxin exhibit CD14/LBP dependent and independent binding that is influenced by endotoxin concentration. Eur J Biochem 267:2218-2226.
38. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, and Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Wash DC) 249:1431-1433.
39. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, and Akira S (2003) TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4:1144-1150.
40. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, and Akira S (2002) A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J Immunol 169:6668-6672.